青岛百洋医药股份有限公司（以下简称"公司"）第四届董事会第三次会议 于 2025 年 11 月 19 日以现场结合通讯的方式召开，会议通知已于 2025 年 11 月 13 日以邮件形式送达全体董事。本次会议由公司董事长付钢先生召集并主持， 应出席董事 9 人，实际出席董事 9 人，公司总经理、董事会秘书列席会议。本次 会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的 规定，会议决议合法、有效。 二、董事会会议审议情况 | 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-099 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、第四届董事会第三次会议决议； 2、第四届董事会审计委员会第三次会议决议； 3、第四届董事会第二次独立董事专门会议决议； 审议通过了《关于关联方向全资子公司增资暨关联交易的议案》。 Zap Therapeut ...

青岛百洋医药股份有限公司 关于关联方向全资子公司增资暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、关联交易概述 为满足河北百洋萨普医疗设备科技有限公司（以下简称"百洋萨普"）的经 营发展需求，增强其资本实力，百洋萨普拟引入 Zap Therapeutic Solutions Limited （以下简称"Zap Therapeutic"）增资 490 万美元。百洋萨普系青岛百洋医药股份 有限公司（以下简称"公司"）全资子公司百洋健康产业国际商贸有限公司（以 下简称"百洋健康"）持股 100%的公司，百洋健康放弃本次增资的优先认缴出资 权。本次增资完成后，百洋萨普的注册资本将由 510 万美元增加至 1,000 万美元， 百洋健康的持股比例将下降至 51%，本次交易不会导致公司合并报表范围变更。 Zap Therapeutic 为 Zap Medical System, Ltd.的全资子公司，Zap Medical System, Ltd.为公司间接参股的公司且公司高级管理人员王廷伟担任其董事。根据 《深圳证券交易所创业板股票上市规则》相关 ...

Market Overview - The pharmaceutical commercial sector declined by 1.33% on November 19, with Renmin Tongtai leading the losses [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while Renmin Tongtai fell by 9.99% to 15.95 [2][1] - The trading volume for Jianfa Zhixin was 180,800 shares, with a transaction value of 620 million yuan [1] - Other notable stocks included Yifeng Pharmacy, which increased by 0.46%, and Shanghai Pharmaceuticals, which decreased by 0.39% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 436 million yuan from institutional investors, while retail investors saw a net inflow of 408 million yuan [2] - The data indicates that retail investors are more active in the sector despite the overall decline in stock prices [2] Individual Stock Capital Flow - Jianfa Zhixin had a net inflow of 70.39 million yuan from institutional investors, while Renmin Tongtai saw a significant outflow of 1.20 billion yuan from retail investors [3] - Other stocks like Guoyao Yizhi and Zhongyao Holdings also experienced mixed capital flows, with Guoyao Yizhi having a net inflow of 7.36 million yuan from institutional investors [3]

Core Insights - BaiLi TianHeng announced the successful interim analysis of its first-in-class EGFR×HER3 dual antibody ADC (iza-bren) in a Phase III clinical trial for esophageal squamous cell carcinoma, achieving both progression-free survival (PFS) and overall survival (OS) primary endpoints [1][2] - The drug has been included in the breakthrough therapy list by the National Medical Products Administration (NMPA) and is expected to submit a pre-market communication application soon, with commercialization anticipated in the domestic market next year [2] Group 1 - The interim analysis of study BL-B01D1-305 showed that iza-bren demonstrated statistically significant benefits in PFS and OS compared to chemotherapy, indicating major clinical benefits [2] - This marks the first ADC drug to achieve dual positive results in a Phase III clinical study for esophageal cancer treatment [1] - Iza-bren has previously shown excellent data in early clinical trials for advanced esophageal squamous cell carcinoma and has been published in the prestigious journal Nature Medicine [2] Group 2 - BaiLi TianHeng focuses on addressing unmet clinical needs in the global biopharmaceutical frontier, particularly in the field of tumor macromolecule therapy, and aims to become a multinational pharmaceutical company (MNC) with global commercialization capabilities by 2029 [3] - The company has established R&D centers in both the US and China, responsible for early product development and subsequent clinical research [3] - BaiLi TianHeng has developed a leading innovative drug R&D platform with global rights and independent intellectual property, including the HIRE-ADC platform, GNC platform, SEBA platform, and HIRE-ARC platform [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 1.62% on November 17, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Renmin Tongtai (600829) with a closing price of 16.64, up 9.98% and a trading volume of 768,000 shares, totaling 1.276 billion yuan [1] - Other stocks in the sector showed mixed results, with several companies like Shanghai Pharmaceuticals (601607) and Guoyao Yizhi (000028) experiencing declines of 1.20% and 1.53% respectively [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 875 million yuan from institutional investors, while retail investors contributed a net inflow of 674 million yuan [2] - The data indicates that retail investors were more active in the market compared to institutional investors during this period [2] Individual Stock Capital Flow - Key stocks with significant capital flow include: - Shuyuan Pingmin (301017) with a net inflow of 17.85 million yuan from institutional investors, while retail investors had a net outflow of 35.94 million yuan [3] - Nanjing Pharmaceutical (600713) had a net inflow of 17.30 million yuan from institutional investors, but also saw outflows from retail investors [3] - Guoyao Yizhi (000028) and Shanghai Pharmaceuticals (601607) also experienced mixed capital flows, with institutional inflows but retail outflows [3]

11月14日，百洋医药跌0.79%，成交额1.01亿元。两融数据显示，当日百洋医药获融资买入额801.39万 元，融资偿还1207.93万元，融资净买入-406.53万元。截至11月14日，百洋医药融资融券余额合计4.85 亿元。 融资方面，百洋医药当日融资买入801.39万元。当前融资余额4.84亿元，占流通市值的3.84%，融资余 额超过近一年80%分位水平，处于高位。 截至9月30日，百洋医药股东户数1.11万，较上期减少40.83%；人均流通股47194股，较上期增加 68.99%。2025年1月-9月，百洋医药实现营业收入56.27亿元，同比减少8.41%；归母净利润4.76亿元，同 比减少25.67%。 分红方面，百洋医药A股上市后累计派现15.51亿元。近三年，累计派现12.01亿元。 机构持仓方面，截止2025年9月30日，百洋医药十大流通股东中，香港中央结算有限公司位居第十大流 通股东，持股290.97万股，为新进股东。工银前沿医疗股票A（001717）退出十大流通股东之列。 责任编辑：小浪快报 融券方面，百洋医药11月14日融券偿还200.00股，融券卖出0.00股，按当日收盘价计算，卖出 ...

Core Insights - The pharmaceutical commercial sector experienced a rise of 1.05% on November 14, with significant gains led by the stock of Jiyu Pingmin, which surged by 20.03% [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jiyu Pingmin (301017) closed at 16.66 with a gain of 20.03%, trading volume of 141,800 shares and a transaction value of 227 million [1] - Renmin Tongtai (600829) and Kaikai Industry (600272) also saw notable increases of 10.04% and 10.03%, respectively [1] - The pharmaceutical sector's stocks showed a mixed performance, with some stocks like Jianfa Zhixin (301584) and Runda Medical (603108) declining by 3.33% and 1.59% respectively [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million from institutional investors, while retail investors contributed a net inflow of 590 million [2][3] - The main stocks experiencing significant net inflows from retail investors included Jiyu Pingmin and Kaikai Industry, while institutional investors showed a preference for stocks like Kaikai Industry [3]

| 证券代码:301015 | | --- | | 倩券代码:123194 | 证券代码：301015 证券简称：百洋医药 公告编号：2025-097 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 关于为子公司提供担保的进展公告 近日，为满足日常经营资金需求，百洋诚达向招商银行股份有限公司廊坊分行 （以下简称"招商银行"）申请了综合授信额度。为支持子公司的业务发展，公司 出具了《最高额不可撤销担保书》，为上述授信额度提供连带责任保证担保，担保 授信本金余额最高限额为人民币 5,000 万元。本次担保事项在前述担保额度范围内， 无需另行召开董事会及股东会审议。 本次担保前公司对百洋诚达已提供且尚在担保期限内的担保余额为 0 元；本次 担保后公司对百洋诚达已提供且尚在担保期限内的担保余额为 0 元，百洋诚达可用 担保额度为 15,000 万元。 注：担保余额以实际发放贷款余额计算；可用担保额度以签订担保合同后剩余的可用额度 计算。 三、担保书的主要内容 1、保证人：青岛百洋医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近 ...

青岛百洋医药股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押的基本情况 青岛百洋医药股份有限公司（以下简称"公司"）近日接到公司控股股东百洋 医药集团有限公司函告，获悉其所持有本公司的部分股份办理了质押业务，具体 事项如下： | 证券代码: | 301015 | | --- | --- | | 倩券代码: | 123194 | 证券代码：301015 证券简称：百洋医药 公告编号：2025-098 债券代码：123194 债券简称：百洋转债 | | | | 本次质 | | | | | 已质押股份情况 | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 持股数 | 持股比 | 押前质 | 本次质押后 | 占其所 | 占公司 | 已质押股 | | 未质押股 | 占未 | | 股东名称 | 量（股） | 例 | 押股份 | 质押股份数 | 持股份 | 总股本 | 份限售和 | 占已质 | ...

中国经济网北京11月14日讯百洋医药（301015）(301015.SZ)昨日晚间发布公告称，近日，公司收到控 股股东百洋医药集团有限公司(以下简称"百洋集团")出具的《关于减持计划期限届满暨实施情况的告知 函》，截至2025年11月11日，本次减持计划的实施期限已届满。 百洋医药于2025年7月21日披露了《关于控股股东减持股份预披露公告》，百洋集团计划通过集中竞价 和(或)大宗交易方式减持百洋医药股份不超过15,768,585股(占百洋医药总股本3.00%)，减持期间为自预 披露公告披露之日起15个交易日后的三个月内(即2025年8月12日-2025年11月11日)。 另据百洋医药同日发布的关于控股股东部分股份解除质押的公告，百洋集团所持有百洋医药的 10,000,000股于2025年11月10日完成了解除质押，占其所持股份比例2.83%，占百洋医药总股本比例 1.90%。截至公告披露日，百洋集团累计质押百洋医药股份数量163,674,652股，占其所持股份比例 46.33%，占百洋医药总股本比例31.14%；百洋集团及其一致行动人合计累计质押百洋医药股份数量 182,254,652股，占其所持股份比例4 ...